Literature DB >> 20513319

Predictors of initiating rapid-acting insulin analog using vial/syringe, prefilled pen, and reusable pen devices in patients with type 2 diabetes.

Lauren J Lee1, Julie Anderson, Shonda A Foster, Sheila M Corrigan, David M Smith, Suellen Curkendall.   

Abstract

BACKGROUND: Limited data are available on the predictors of insulin delivery device choice. This study assessed the patient- and health-care-system-related factors that predict the initiation of one rapid-acting insulin analog (RAIA) delivery system over another.
METHODS: A retrospective analysis using a claims database (January 1, 2007, through March 31, 2009) was conducted. Patients were required to be diagnosed with type 2 diabetes mellitus, and have >or=12 months of continuous eligibility prior to their first prescription of a RAIA on or after January 1, 2008. The three cohorts in the study were vial/syringe (n = 6820), prefilled pen (n = 5840), and reusable pen (n = 2052). Multiple factors were examined using stepwise logistic regression.
RESULTS: Factors that increased the likelihood of initiating RAIA using prefilled pen versus vial/syringe included endocrinologist visit [odds ratio (OR) = 3.13, 95% confidence interval (CI) = 2.56, 3.82], prior basal insulin use with pen (OR = 4.85, 95% CI = 4.21, 5.59), and use of >or=1 oral antihyperglycemic agents (OR = 1.32, 95% CI = 1.20, 1.45). Factors that decreased the likelihood included inpatient admission (OR = 0.76, 95% CI = 0.70, 0.83), nursing home visit (OR = 0.22, 95% CI = 0.18, 0.27), and obesity (OR = 0.67, 95% CI = 0.53, 0.83). There were fewer differences between prefilled and reusable pen initiators. Factors that increased the likelihood of initiating with prefilled versus reusable pen included endocrinologist visit (OR = 1.87, CI = 1.50, 2.34) and inpatient admission (OR = 1.46, 95% CI = 1.30, 1.64).
CONCLUSION: Significant differences in predictors were observed between prefilled pen and vial/syringe initiators. The differences were fewer between prefilled and reusable pen initiators. These differences should be taken into consideration when evaluating outcomes associated with specific insulin delivery systems. (c) 2010 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20513319      PMCID: PMC2901030          DOI: 10.1177/193229681000400307

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  23 in total

1.  Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits.

Authors:  C N Sadur; N Moline; M Costa; D Michalik; D Mendlowitz; S Roller; R Watson; B E Swain; J V Selby; W C Javorski
Journal:  Diabetes Care       Date:  1999-12       Impact factor: 19.112

2.  Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.

Authors:  Won Chan Lee; Sanjeev Balu; David Cobden; Ashish V Joshi; Chris L Pashos
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

Review 3.  Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe.

Authors:  Cliff Molife; Lauren J Lee; Lizheng Shi; Monika Sawhney; Sheila M Lenox
Journal:  Diabetes Technol Ther       Date:  2009-08       Impact factor: 6.118

4.  Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.

Authors:  David Cobden; Won Chan Lee; Sanjeev Balu; Ashish V Joshi; Chris L Pashos
Journal:  Pharmacotherapy       Date:  2007-07       Impact factor: 4.705

5.  Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.

Authors:  Manjiri D Pawaskar; Fabian T Camacho; Roger T Anderson; David Cobden; Ashish V Joshi; Rajesh Balkrishnan
Journal:  Clin Ther       Date:  2007-06       Impact factor: 3.393

6.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

7.  Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin.

Authors:  Carrie McAdam-Marx; Junhua Yu; Jonathan Bouchard; Mark Aagren; Diana I Brixner
Journal:  Curr Med Res Opin       Date:  2010-01       Impact factor: 2.580

8.  Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.

Authors:  Carol E Koro; Steven J Bowlin; Nancy Bourgeois; Donald O Fedder
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

Review 9.  Medication taking and diabetes: a systematic review of the literature.

Authors:  Peggy Soule Odegard; Kam Capoccia
Journal:  Diabetes Educ       Date:  2007 Nov-Dec       Impact factor: 2.140

10.  The association between diabetes related medical costs and glycemic control: a retrospective analysis.

Authors:  Alan K Oglesby; Kristina Secnik; John Barron; Ibrahim Al-Zakwani; Maureen J Lage
Journal:  Cost Eff Resour Alloc       Date:  2006-01-16
View more
  1 in total

Review 1.  Analysis of symposium articles on insulin pen devices and alternative insulin delivery methods.

Authors:  Devra K Dang; Jennifer Lee
Journal:  J Diabetes Sci Technol       Date:  2010-05-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.